Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO Congress 2021

GSK - First-line PARP inhibitor maintenance therapy in advanced ovarian cancer: improving safety outcomes and the patient experience

Individualized patient care during PARPi maintenance therapy

Date

21 Sep 2021

Session

GSK - First-line PARP inhibitor maintenance therapy in advanced ovarian cancer: improving safety outcomes and the patient experience

Topics

Tumour Site

Ovarian Cancer

Presenters

Antonio González-Martín

Authors

A. González-Martín

Author affiliations

  • Medical Oncology, Grupo Español de Investigación en Cáncer de Ovario (GEICO), Clínica Universidad de Navarra, Madrid/ES

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Login

Resources from the same session

Introduction to PARPi maintenance therapy

Presenter: Alexandra Leary

Session: GSK - First-line PARP inhibitor maintenance therapy in advanced ovarian cancer: improving safety outcomes and the patient experience

Resources:

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.